Please use this identifier to cite or link to this item:
|Title:||Patent Linkage in India: Current Scenario and Need for Deliberation|
|Abstract:||<link rel="File-List" href="file:///C:%5CDOCUME%7E1%5Ccharu%5CLOCALS%7E1%5CTemp%5Cmsohtml1%5C01%5Cclip_filelist.xml"><smarttagtype namespaceuri="urn:schemas-microsoft-com:office:smarttags" name="country-region"><smarttagtype namespaceuri="urn:schemas-microsoft-com:office:smarttags" name="place"> The system of ‘patent linkage’ refers to the practice of linking drug marketing approval to the status of the patent of the originator’s product. It directly affects the entry of generic drugs into the market. The article analyses patent linkage in different jurisdictions and finds out whether such a system can be read into existing Indian laws. It also discusses various judicial pronouncements and pertinent legislations to trace the history and scope of patent linkage in India. The Delhi High Court judgment, in <i style="">Bayer Corporation and Others </i>v<i style=""> Cipla, Union of India (UOI) and Others</i><sup>1</sup><i style="">, </i>which held that patent linkage cannot be read into existing Indian provisions, has been discussed in detail. This article tries to highlight the reasons as to why such a system should, or should not, be introduced in India. </smarttagtype></smarttagtype>|
|ISSN:||0975-1076 (Online); 0971-7544 (Print)|
|Appears in Collections:||JIPR Vol.15(3) [May 2010]|
Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.